Genetic Background Amplifies the Effect of Immunodeficiency in Antibiotic Efficacy Against Borrelia burgdorferi

J Infect Dis. 2021 Jul 15;224(2):345-350. doi: 10.1093/infdis/jiaa719.

Abstract

Unrecognized immunodeficiency has been proposed as a possible cause of failure of antibiotics to resolve symptoms of Lyme disease. Here, we examined the efficacy of doxycycline in different immunodeficient mice to identify defects that impair antibiotic treatment outcomes. We found that doxycycline had significantly lower efficacy in the absence of adaptive immunity, specifically B cells. This effect was most pronounced in immunodeficient C3H mice compared with C57BL/6 mice, suggesting a role for genetic background beyond immunodeficiency. Addition of a single dose of ceftriaxone to doxycycline treatment effectively cleared infection in C3H mice with severe combined immunodeficiency.

Keywords: Borrelia burgdorferi; Lyme disease; antibiotics.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents* / therapeutic use
  • Borrelia burgdorferi
  • Doxycycline
  • Genetic Background*
  • Immunologic Deficiency Syndromes* / genetics
  • Lyme Disease* / drug therapy
  • Lyme Disease* / genetics
  • Mice
  • Mice, Inbred C3H
  • Mice, Inbred C57BL

Substances

  • Anti-Bacterial Agents
  • Doxycycline